secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001818331-25-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance
----------------------------------------------------------------------------

- Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.
- Q4 2024 revenue at least $92M (+59% YoY, +20% sequential); exome/genome rev $75.8M (+93% YoY).
- Adjusted gross margin ≥64% FY (guidance ≥62%) and ≥68% in Q4 (up from 64% Q3).
- Q4 exome/genome volume 20,676 (+32% YoY, +7% seq); expects second consecutive adjusted net income quarter and first positive operating cash flow.
- Includes $6.8M discrete benefit from multi-year appeal recovery from a single payer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000004/0001818331-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000004/wgs-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001818331-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer